Evidence map›Paper›PMID 30023604›Full record

ArticleACS omega2017

Indolizine-Based Scaffolds as Efficient and Versatile Tools: Application to the Synthesis of Biotin-Tagged Antiangiogenic Drugs.

Marie Arvin-Berod, Agnès Desroches-Castan, Simon Bonte, Sabine Brugière, Yohann Couté, Laurent Guyon, Jean-Jacques Feige, Isabelle Baussanne, Martine Demeunynck

Open access · goldAbstract read
In one paragraph

Article in ACS omega, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 26 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Marie Arvin-BerodUniv. Grenoble Alpes, CNRS, DPM, 38000 Grenoble, France.
Agnès Desroches-CastanUniv. Grenoble Alpes, Inserm, CEA, BIG-BCI, 38000, Grenoble, France.
Simon BonteUniv. Grenoble Alpes, CNRS, DPM, 38000 Grenoble, France.
Sabine BrugièreUniv. Grenoble Alpes, CEA, Inserm, BIG-BGE, 38000 Grenoble, France.
Yohann CoutéUniv. Grenoble Alpes, CEA, Inserm, BIG-BGE, 38000 Grenoble, France.
Laurent GuyonUniv. Grenoble Alpes, Inserm, CEA, BIG-BCI, 38000, Grenoble, France.
Jean-Jacques FeigeUniv. Grenoble Alpes, Inserm, CEA, BIG-BCI, 38000, Grenoble, France.
Isabelle BaussanneUniv. Grenoble Alpes, CNRS, DPM, 38000 Grenoble, France.
Martine DemeunynckUniv. Grenoble Alpes, CNRS, DPM, 38000 Grenoble, France.
Inserm · FRCentre National de la Recherche Scientifique · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We describe the design and optimization of polyfunctional scaffolds based on a fluorescent indolizine core derivatized with various orthogonal groups (amines, esters, oximes, alkynes, etc.). To show one application as tools in biology, the scaffold was used to prepare drug-biotin conjugates that were then immobilized onto avidin-agarose for affinity chromatography. More specifically, the antiangiogenic drug COB223, whose mechanism of action remained unclear, was chosen as a proof-of-concept drug. The drug-selective discrimination of proteins observed after elution of the cell lysates through the affinity columns, functionalized either with the biologically active COB223 or a structurally related inactive analogue (COB236), is a clear indication that the presence of the indolizine core does not limit drug-protein interaction and confirms the usefulness of the indolizine scaffold. Furthermore, the separation of COB223-interacting proteins from human placental extracts unveiled unanticipated protein targets belonging to the family of regulatory RNA-binding proteins, which opens the way to new hypotheses on the mode of action of this antiangiogenic drug.

Identifiers

PMID30023604
PMCPMC6044919
OpenAlexW2775953103

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.